Multicomponent therapeutics for networked systems
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Therapeutic regimens that comprise more than one active ingredient are commonly used in clinical medicine. Despite this, most drug discovery efforts search for drugs that are composed of a single chemical entity. A focus in the early drug discovery process on identifying and optimizing the activity of combinations of molecules can result in the identification of more effective drug regimens. A systems perspective facilitates an understanding of the mechanism of action of such drug combinations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1705]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“There have been attempts to systematize a set of principles that can account for combination drugs that exist toda”
BackgroundLessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419 · cited 1×
“Numerous researchers have attempted to provide an unambiguous framework for the calculation of additive effects between compounds; these approaches are reviewed comprehensively elsewher”
BackgroundSystematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants
Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science · doi:10.1126/science.1065810 · Cited by 2,138
A N EW A PPROACH TO D ECODING L IFE : Systems Biology
Ideker, T., Galitski, T., & Hood, L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.343 · Cited by 1,664 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundDolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Self-citation
Research works printed but not linked: 2
- Ehrlich, P. Chemotherapeutics: scientific principles, methods and results. Lancet 2, 445–451 (1913).
- Albert, A. Selective Toxicity (Methuen & Co., London, 1968).
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
How antibiotics kill bacteria: from targets to networks
Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2333 · Cited by 2,258
Curcumin as “Curecumin”: From kitchen to clinic
Goel, A., Kunnumakkara, A. B., & Aggarwal, B. B. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.016 · Cited by 2,214
“[204] Keith CT, Borisy AA, Stockwell BR.”
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Traditional Chinese medicine network pharmacology: theory, methodology and application
LI, S., & ZHANG, B. (2013) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(13)60037-0 · Cited by 1,329
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
“Since the last century, advances in Omics and Cell Biology have greatly impacted on the increasing use of drug combination in modern medicine (Keith et al. 2005).”
BackgroundMulti-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Self-citationCombinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Mechanisms of drug combinations: interaction and network perspectives
Jia, J., Zhu, F., Ma, X., Cao, Z. W., Li, Y. X., & Chen, Y. Z. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2683 · Cited by 969
Synergistic drug combinations tend to improve therapeutically relevant selectivity
Lehár, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., Rickles, R. J., Short III, G. F., Staunton, J. E., Jin, X., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1549 · Cited by 938
Self-citationThe Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
“• Experimental testing of drug combinations may uncover unexpected effects in drug–drug interactions, which may be used for selection of multi-target sets (Borisy et al., 2003; Keith et al., 2005; Dancey & Chen, 2006; Yeh et al., 2006; Lehár et al., 2007; Jia et al., 2009; Liu et al., 2010b).”
BackgroundDrug combinations: a strategy to extend the life of antibiotics in the 21st century
Tyers, M., & Wright, G. D. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0141-x · Cited by 820
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Multidrug evolutionary strategies to reverse antibiotic resistance
Baym, M., Stone, L. K., & Kishony, R. (2016) · Science · doi:10.1126/science.aad3292 · Cited by 710
Ji, H., Li, X., & Zhang, H. (2009) · EMBO reports · doi:10.1038/embor.2009.12 · Cited by 636
“Their complex evolutionary histories mean that the structures of natural compounds are highly likely to generate secondary effects and their efficacy often depends on synergistic interactions with other components (Keith et al, 2005).”
BackgroundExploring genetic interactions and networks with yeast
Boone, C., Bussey, H., & Andrews, B. J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2085 · Cited by 661
Wang, H., Zhao, Y., Wu, Y., Hu, Y.-L., Nan, K., Nie, G., & Chen, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.032 · Cited by 603
Systems biology and combination therapy in the quest for clinical efficacy
Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006) · Nature Chemical Biology · doi:10.1038/nchembio817 · Cited by 570
“The combined effect of the rocks and nails can then be found by correctly combining the individual probabilities that an egg will be hit as the union of independent rock and nail events, which after rearrangement results in equation (5).”
BackgroundMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“Another set of predictions from the systems biology perspective is that combinations [1535-1539; 1562; 2089; 2090] of chemical agents will be far more efficacious in modulating iron-catalysed oxidative stress and its sequelae than will be the use of ‘magic bullet’ single agents.”
BackgroundGan, B. H., Gaynord, J., Rowe, S. M., Deingruber, T., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00729c · Cited by 511
Effect of antibiotics in the environment on microbial populations
Ding, C., & He, J. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-2649-5 · Cited by 465
“Considering the various types of combined effects of antibiotics (Keith et al. 2005; Yeh et al. 2006), it is expected that the coexistence of two or even more antibiotics in soil or aquatic environment will present a different effect from when they are acting alone.”
BackgroundA robustness-based approach to systems-oriented drug design
Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 480
“Multi-target agents directed at selected multiple targets have been increasingly explored for enhanced therapeutic efficacies, improved safety profiles and reduced resistance activities by simultaneously modulating the activity of a primary target and the counteractive elements (3,37,38).”
BackgroundDrug Combinations in Breast Cancer Therapy
Fisusi, F. A., & Akala, E. O. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190122111224 · Cited by 449
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Antibiotic interactions that select against resistance
Chait, R., Craney, A., & Kishony, R. (2007) · Nature · doi:10.1038/nature05685 · Cited by 439
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Tessellated multiporous two-dimensional covalent organic frameworks
Jin, Y., Hu, Y., & Zhang, W. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0056 · Cited by 421
Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation
Cegelski, L., Pinkner, J. S., Hammer, N. D., Cusumano, C. K., Hung, C. S., Chorell, E., Åberg, V., Walker, J. N., Seed, P. C., Almqvist, F., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.242 · Cited by 417
Din, F. V. N., Valanciute, A., Houde, V. P., Zibrova, D., Green, K. A., Sakamoto, K., Alessi, D. R., & Dunlop, M. G. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.050 · Cited by 418
Comparative Absorption of a Standardized Curcuminoid Mixture and Its Lecithin Formulation
Cuomo, J., Appendino, G., Dern, A. S., Schneider, E., McKinnon, T. P., Brown, M. J., Togni, S., & Dixon, B. M. (2011) · Journal of Natural Products · doi:10.1021/np1007262 · Cited by 339
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
“out to discover unexpected synergistic interactions, as exemplified by the combination of the anti-parasitic drug pentamidine with antipsychotic chlorpromazine that that has synergistic anti-mitotic activity in vitro [27, 28].”
BackgroundLi, S., Zhang, B., & Zhang, N. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-s1-s10 · Cited by 380
“Multicomponent therapeutics, in which two or more agents interact with multiple targets simultaneously, is considered as a rational and efficient form of therapy designed to control complex diseases [1,2].”
BackgroundNetwork‐based Approaches in Pharmacology
Boezio, B., Audouze, K., Ducrot, P., & Taboureau, O. (2017) · Molecular Informatics · doi:10.1002/minf.201700048 · Cited by 359
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…2006; Borisy et al. 2003; Csermely et al. 2005; Dancey and Chen 2006; Fan et al. 2003, 2006; Haggarty et al. 2003; Hopkins et al. 2006; Kaelin 2005; Keith et al. 2005; Kostoff and Delafuente 2006; Millan 2006; Perlstein et al. 2006; Sharom et al. 2004; Shiomi et al. 1999; Wermuth…”
BackgroundFunctional classification of drugs by properties of their pairwise interactions
Yeh, P., Tschumi, A. I., & Kishony, R. (2006) · Nature Genetics · doi:10.1038/ng1755 · Cited by 350
Duarte, D., & Vale, N. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100110 · Cited by 340
Reuter, S., Eifes, S., Dicato, M., Aggarwal, B. B., & Diederich, M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.031 · Cited by 336
“Therefore it is becoming imperative to adopt a multi-target based drug development paradigm for the treatment of complex human diseases [124,125] that work by different mechanisms of action, thereby leading them to decrease the probability that cancer cells will develop resistance against chemotherapeutic”
BackgroundDual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
A community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321
Network Pharmacology: A New Approach for Chinese Herbal Medicine Research
Zhang, G.-B., Li, Q.-Y., Chen, Q.-L., & Su, S.-B. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/621423 · Cited by 300
“The increased understanding of the role of network biology systems challenges the dominant assumption of single-target drug discovery [11, 12].”
BackgroundCompatibility art of traditional Chinese medicine: From the perspective of herb pairs
Wang, S., Hu, Y., Tan, W., Wu, X., Chen, R., Cao, J., Chen, M., & Wang, Y. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.07.033 · Cited by 313
“For a long period of time, medical scientists have realized that the pathogenesis and progression of diseases are so complicated that the therapeutic effect of a single drug may be modest and hampered by various side effects or resistances in clinic (Keith et al., 2005; Zhao et al., 2010).”
BackgroundUtilizing graph machine learning within drug discovery and development
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313
The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Something old, something new: revisiting natural products in antibiotic drug discovery
Wright, G. D. (2014) · Canadian Journal of Microbiology · doi:10.1139/cjm-2014-0063 · Cited by 283
“The combination of antibiotics with antibiotics (so-called congruous pairs (Keith et al. 2005)) has been a mainstay of anti-infective chemotherapy for over 60 years (Moellering 1983).”
BackgroundAntimicrobial blue light inactivation of pathogenic microbes: State of the art
Wang, Y., Wang, Y., Wang, Y., Murray, C. K., Hamblin, M. R., Hooper, D. C., & Dai, T. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.002 · Cited by 296
“It is commonly accepted that synergistic combinations of two or more agents can overcome toxicity and other side effects associated with high doses of single drugs by countering biological compensation, allowing reduced dose of each compound or accessing context-specific multi-target mechanisms (Keith et al., 2005).”
BackgroundMetabolomics: from pattern recognition to biological interpretation
Weckwerth, W., & Morgenthal, K. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03609-3 · Cited by 298
Drug repurposing in oncology—patient and health systems opportunities
Bertolini, F., Sukhatme, V. P., & Bouche, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.169 · Cited by 294
Modulation of cytokine expression by traditional medicines: a review of herbal immunomodulators.
Spelman, K., Burns, J. J., Nichols, D., Winters, N., Ottersberg, S., & Tenborg, M. (2006) · PubMed · Cited by 372
Li, S., Zhang, B., Jiang, D., Wei, Y., & Zhang, N. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s11-s6 · Cited by 275
“TCM formula is considered to be an empirical system of multicomponent therapeutics which potentially meets the demands of treating a number of complex diseases in an integrated manner [3,14,15].”
BackgroundRepurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
Verbaanderd, C., Maes, H., Schaaf, M. B., Sukhatme, V. P., Pantziarka, P., Sukhatme, V., Agostinis, P., & Bouche, G. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.781 · Cited by 275
Biological network analysis with deep learning
Muzio, G., O’Bray, L., & Borgwardt, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa257 · Cited by 248
“Subsequently, we discuss the increased interest focused on the identification of which combination of drugs, known as polypharmacy, can be effective for treating human diseases whose mechanisms are too complicated to be treated by using a single one [106].”
Light-controlled nitric oxide delivering molecular assemblies
Sortino, S. (2010) · Chemical Society Reviews · doi:10.1039/b908663n · Cited by 277
Chemical combination effects predict connectivity in biological systems
Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100116 · Cited by 275
“We have previously reported an approach for high-throughput dose-& matrix screening of chemical combinations (Borisy et al , 2003; Keith et al , 2005; Zimmermann et al , 2007) in cell-based assays that preserve disease-relevant biological connections.”
Self-citationFarha, M. A., Verschoor, C. P., Bowdish, D., & Brown, E. D. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.07.006 · Cited by 278
“Indeed, drug combination therapy is gaining favor (Keith et al., 2005) because of increased efficacy, lower toxicity, and reduced propensity for resistance (Cottarel and Wierzbowski, 2007).”
BackgroundAntimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution
Bollenbach, T. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.05.008 · Cited by 261
“Introduction Drug combinations are increasingly used in the treatment of many conditions and diseases including tuberculosis and cancer [1,2].”
BackgroundMetal-organic frameworks: A novel platform for combined advanced therapies
Rojas, S., Arenas-Vivo, A., & Horcajada, P. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.02.032 · Cited by 261
Weinreb, O., Amit, T., Mandel, S., & Youdim, M. B. H. (2009) · Genes & Nutrition · doi:10.1007/s12263-009-0143-4 · Cited by 242
“some combinations do induce a favorable clinical response, not achieved by each of the drugs given alone [51].”
BackgroundPolypharmacology: The science of multi-targeting molecules
Kabir, A., & Muth, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106055 · Cited by 221
Combination drugs, an emerging option for antibacterial therapy
Cottarel, G., & Wierzbowski, J. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.09.004 · Cited by 237
Tamae, C., Liu, A., Kim, K., Sitz, D., Hong, J., Becket, E., Bui, A., Solaimani, P., Tran, K. P., Yang, H., et al. (2008) · Journal of Bacteriology · doi:10.1128/jb.01982-07 · Cited by 234
“Small molecules with antimicrobial properties can be characterized in any one of a number of ways, such as by their spectrum of activity on different bacterial strains, their effects on transcription at subinhibitory or inhibitory concentrations (19, 62, 63), or the type of synergistic interactions displayed with othe…”
BackgroundMulti‐targeted therapy by curcumin: how spicy is it?
Goel, A., Jhurani, S., & Aggarwal, B. B. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700354 · Cited by 228
Rapid screening of antibiotic toxicity in an automated microdroplet system
Churski, K., Kaminski, T. S., Jakiela, S., Kamysz, W., Baranska-Rybak, W., Weibel, D. B., & Garstecki, P. (2012) · Lab on a Chip · doi:10.1039/c2lc21284f · Cited by 228
Nonoptimal microbial response to antibiotics underlies suppressive drug interactions
Bollenbach, T., Quan, S., Chait, R., & Kishony, R. (2009) · Cell · doi:10.1016/j.cell.2009.10.025 · Cited by 227
“Drug combinations can be an important tool for studying biological systems and revealing relationships between different cellular processes (Keith et al., 2005; Lehá r et al., 2008, 2007; Tsui et al., 2004).”
BackgroundChen, B., Dong, X., Jiao, D., Wang, H., Zhu, Q., Ding, Y., & Wild, D. J. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-255 · Cited by 222
“However, divergent and redundant pathways in humans often enable a system to keep functioning if one pathway is blocked as there is an alternative pathway to compensate [37].”
BackgroundMultifunctional compounds: Smart molecules for multifactorial diseases
Bansal, Y., & Silakari, O. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.060 · Cited by 212
Weth, F. R., Hoggarth, G. B., Weth, A. F., Paterson, E., White, M. P. J., Tan, S. T., Peng, L., & Gray, C. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02502-9 · Cited by 197
“The testing of combination therapy, which would focus on the numerous compromised cellular pathways, would be more appropriate for many cancer patients [125].”
BackgroundFinding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery
O'Connor, K. A., & Roth, B. L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1900 · Cited by 215
Rescuing drug discovery: in vivo systems pathology and systems pharmacology
van der Greef, J., & McBurney, R. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1904 · Cited by 209
Bulusu, K. C., Guha, R., Mason, D. J., Lewis, R. P. I., Muratov, E., Kalantar Motamedi, Y., Cokol, M., & Bender, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.003 · Cited by 202
Fragments, network biology and designing multiple ligands
Morphy, R., & Rankovic, Z. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.12.006 · Cited by 204
Molecular networks for the study of TCM Pharmacology
Zhao, J., Jiang, P., & Zhang, W. (2010) · Briefings in Bioinformatics · doi:10.1093/bib/bbp063 · Cited by 204
“digm [1–5], the drug discovery field is showing an”
BackgroundHigh-Throughput Methods for Combinatorial Drug Discovery
Sun, X., Vilar, S., & Tatonetti, N. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006667 · Cited by 197
The Art and Practice of Systems Biology in Medicine: Mapping Patterns of Relationships
van der Greef, J., Martin, S., Juhasz, P., Adourian, A., Plasterer, T., Verheij, E. R., & McBurney, R. N. (2007) · Journal of Proteome Research · doi:10.1021/pr0606530 · Cited by 201
Models for prevention and treatment of cancer: Problems vs promises
Aggarwal, B. B., Danda, D., Gupta, S., & Gehlot, P. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.027 · Cited by 179
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
“Instead, unbiased screens for synergistic enhancers of a specific bioactivity that are not themselves active, sometimes termed syncretic combinations, are needed to fully explore chemical space (Keith et al, 2005).”
Models from experiments: combinatorial drug perturbations of cancer cells
Nelander, S., Wang, W., Nilsson, B., She, Q., Pratilas, C., Rosen, N., Gennemark, P., & Sander, C. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.53 · Cited by 187
“For example, combination of targeted drugs is considered a promising strategy to improve treatment efficacy, reduce off-target effects and/or prevent evolution drug resistance (Borisy et al , 2003; Keith et al , 2005; Komarova and Wodarz, 2005; Chou, 2006).”
BackgroundAlbertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
Liu, Y., Fang, J., Kim, Y.-J., Wong, M. K., & Wang, P. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5000373 · Cited by 172
Amirouchene-Angelozzi, N., Nemati, F., Gentien, D., Nicolas, A., Dumont, A., Carita, G., Camonis, J., Desjardins, L., Cassoux, N., Piperno-Neumann, S., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.004 · Cited by 166
Functionalized graphene oxide as a vehicle for targeted drug delivery and bioimaging applications
Karki, N., Tiwari, H., Tewari, C., Rana, A., Pandey, N., Basak, S., & Sahoo, N. G. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01149e · Cited by 169
Nandy, J. P., Prakesch, M., Khadem, S., Reddy, P. T., Sharma, U., & Arya, P. (2009) · Chemical Reviews · doi:10.1021/cr800188v · Cited by 171
Lehár, J., Stockwell, B. R., Giaever, G., & Nislow, C. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.120 · Cited by 172
Self-citationGinsburg, H., & Deharo, E. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-s1-s1 · Cited by 162
“secondary metabolites which might act in concert to enhance the therapeutic effect [26,27].”
BackgroundYang, R., Jang, H., Stocker, R., & Gleason, K. K. (2014) · Advanced Materials · doi:10.1002/adma.201304386 · Cited by 164
How to design multi-target drugs: target search options in cellular networks
Korcsmáros, T., Szalay, M., Böde, C., Kovács, I. A., & Csermely, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.6.799 · Cited by 186
“As one of the newly developed combination therapies, ‘multi-target lead discovery’ is a promising tool for the identification of unexpectedly novel effects of drug combinations [4-8] .”
BackgroundOptimal Drug Synergy in Antimicrobial Treatments
Torella, J. P., Chait, R., & Kishony, R. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000796 · Cited by 162
“between the drugs respectively [6–9].”
Systems biology approaches for advancing the discovery of effective drug combinations
Ryall, K. A., & Tan, A. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0055-9 · Cited by 159
“Table 1 Resources for systems analysis of drug combinations results, making it easier to compute [19].”
BackgroundWhere is the hope for drug discovery? Let history tell the future
De, K., Li, X., & Zhang, H. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.002 · Cited by 179
Wang, X., Zhang, A., Wang, P., Sun, H. J., Wu, G., Sun, W., Lv, H., Jiao, G., Xu, H., Yuan, Y., et al. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.021683 · Cited by 157
“used clinically in Chinese medicine (15).”
Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegans
Voisine, C., Varma, H., Walker, N., Bates, E. A., Stockwell, B. R., & Hart, A. C. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000504 · Cited by 156
“In Figure 4d, Bliss Independence was assessed [30].”
Self-citationStructure-based systems biology for analyzing off-target binding
Xie, L., Xie, L., & Bourne, P. E. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.01.004 · Cited by 163
“The understanding of the drug response at the systems level is particularly important for understanding polypharmacology since there are many reported examples where the therapeutic efficacy is enhanced through synergistic relationships among multiple targets [107–111].”
BackgroundPhytotherapy in diabetes: Review on potential mechanistic perspectives
El-Abhar, H. S., & Schaalan, M. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.176 · Cited by 145
In-Silico Approaches to Multi-target Drug Discovery
Xiao, H., Shi, Z., Tan, C., Jiang, Y., Go, M., Low, B. C., & Chen, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0065-2 · Cited by 152
“6 and 7 respectively.”
Background
Metadata
- Authors
- Keith, C. T., Borisy, A. A., & Stockwell, B. R.
- Affiliations
- Columbia University (US)
- Corresponding author
- Keith, Curtis T.
- Borisy, Alexis A.
- Stockwell, Brent R.
- ORCID
- Stockwell, Brent R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-01
- Volume
- 4
- Issue
- 1
- Pages
- 71-78
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1592483428
- Cited by
- 769
- References
- 67
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 30 · 2023: 33 · 2022: 44 · 2021: 36 · 2020: 34 · 2019: 36 · 2018: 42 · 2017: 29 · 2016: 43 · 2015: 51 · 2014: 55 · 2013: 49 · 2012: 47
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Burroughs Wellcome Fund
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- combination therapy, systems biology, mechanism of action, drug discovery
- MeSH terms
- Clinical Trials as Topic, Drug Synergism, Drug Therapy, Combination, Humans, Terminology as Topic, Drug Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.